Cover Image
市場調查報告書

Brexpiprazole (重度憂鬱症)-預測與市場分析

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 305484
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
Brexpiprazole (重度憂鬱症)-預測與市場分析 Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023
出版日期: 2014年05月30日 內容資訊: 英文 63 Pages
簡介

重度憂鬱症(MDD)是世界最常見的精神疾病之一。其市場競爭激烈,有超過30個產品上市中。在Eli Lilly的Cymbalta、大塚製薬/BMS的Abilify等主力產品專利即將到期,及Lundbeck/武田薬品工業的Brintellix等位於最終階段平台產品即將上市的當下,市場正在大大變化中。Brexpiprazole當初雖然是由大塚製藥所開發,但2011年與Lundbeck簽下契約,共同開發為MDD輔助治療藥,以及精神分裂症、焦慮症、癡呆症、PTSD、睡眠障礙、ADHD的治療藥,目前在美國及歐洲正位於第三期開發階段。

本報告提供重度憂鬱症的治療藥物Brexpiprazole之調查分析,為您提供疾病概要和治療指南,競爭情形,產品資訊,銷售額預測等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀及亞型
  • 預後
  • QOL

第4章 疾病的管理

  • 症狀和治療概要

第5章 競爭評估

  • 概要

第6章 機會及未滿足需求

  • 概要
  • 更有效的藥物療法
  • 更佳副作用簡介
  • 效果快速的抗憂鬱效果
  • 個人化醫療的方法

第7章 開發平台分析

  • 概要
  • 臨床開發中的潛力藥物

第8章 Brexpiprazole (OPC-34712)

  • 概要
  • 功效
  • 安全性
  • 給藥與處方
  • 臨床及市場上的潛在地位
  • SWOT分析
  • 預測

第9章 附錄

圖表

目錄
Product Code: GDHC425DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Otsuka Pharmaceutical initially developed Brexpiprazole but in 2011, the pharmaceutical company entered an agreement with Lundbeck for the co-development and co-commercialization of this product. The product is in Phase III development as an adjunctive therapy for MDD in the US and Europe, and is also being developed for the treatment of schizophrenia, anxiety disorders, dementia, post-traumatic stress disorder (PTSD), sleep disorders, and ADHD.

Scope

  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Brexpiprazole including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Brexpiprazole for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Brexpiprazole performance
  • Obtain sales forecast for Brexpiprazole from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Needs and Opportunities

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Needs
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunities
  • 6.3. More Favorable Side Effect Profiles
    • 6.3.1. Unmet Needs
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunities
  • 6.4. Rapid Onset of Antidepressant Effects
    • 6.4.1. Unmet Needs
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunities
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Needs
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunities

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Brexpiprazole (OPC-34712)

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning
  • 8.6. SWOT Analysis
  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed MDD Patients
    • 9.4.2. Percent of Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Directors
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
  • Table 6: Leading Treatments for MDD, 2013
  • Table 7: Unmet Needs and Opportunities in MDD
  • Table 8: Comparison of Therapeutic Classes in Development for MDD, 2013
  • Table 9: Product Profile - Brexpiprazole
  • Table 10: Safety of Brexpiprazole - Most Frequently Reported Adverse Events
  • Table 11: Brexpiprazole SWOT Analysis, 2014
  • Table 12: Global MDD Sales Forecasts ($m) for Brexpiprazole, 2013-2023
  • Table 13: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
  • Figure 4: MDD - Phase IIb-III Pipeline, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023
  • Figure 6: Clinical and Commercial Positioning of Brexpiprazole
Back to Top